Viking Therapeutics has appointed Dorothy Gemmell to its board of directors, effective immediately. Ms. Gemmell brings over 25 years of leadership experience across healthcare, digital health, and commercialization, having served as president or chief commercial officer at companies including GoodRx, Capsule, and Havas Life. Her appointment comes as the clinical-stage biopharmaceutical company advances its next-generation therapies and prepares for the potential launch of VK2735, its lead obesity program currently in Phase 3 clinical studies. Viking's chairman Lawson Macartney noted that her commercial expertise will be valuable as the company executes on its long-term goals.
Viking Therapeutics IncAppointment of experienced commercial executive strengthens leadership ahead of potential VK2735 launch.